126 related articles for article (PubMed ID: 8536548)
1. Growth hormone secretagogues. Clinical experience and therapeutic potential.
Laron Z
Drugs; 1995 Oct; 50(4):595-601. PubMed ID: 8536548
[TBL] [Abstract][Full Text] [Related]
2. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.
Van den Berghe G; Wouters P; Carlsson L; Baxter RC; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1998 Sep; 83(9):3062-70. PubMed ID: 9745404
[TBL] [Abstract][Full Text] [Related]
3. The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Van den Berghe G; de Zegher F; Veldhuis JD; Wouters P; Awouters M; Verbruggen W; Schetz M; Verwaest C; Lauwers P; Bouillon R; Bowers CY
J Clin Endocrinol Metab; 1997 Feb; 82(2):590-9. PubMed ID: 9024260
[TBL] [Abstract][Full Text] [Related]
4. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion.
Merriam GR; Buchner DM; Prinz PN; Schwartz RS; Vitiello MV
Endocrine; 1997 Aug; 7(1):49-52. PubMed ID: 9449031
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children.
Mericq V; Cassorla F; Garcia H; Avila A; Bowers CY; Merriam GR
J Clin Endocrinol Metab; 1995 May; 80(5):1681-4. PubMed ID: 7745018
[TBL] [Abstract][Full Text] [Related]
6. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
[TBL] [Abstract][Full Text] [Related]
7. Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.
Tannenbaum GS; Bowers CY
Endocrine; 2001 Feb; 14(1):21-7. PubMed ID: 11322498
[TBL] [Abstract][Full Text] [Related]
8. Short term continuous intravenous infusion of growth hormone (GH) inhibits GH-releasing hormone-induced GH secretion: a time-dependent effect.
Rosenthal SM; Kaplan SL; Grumbach MM
J Clin Endocrinol Metab; 1989 Jun; 68(6):1101-5. PubMed ID: 2498383
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone secretagogues as diagnostic tools in disease states.
Baldelli R; Otero XL; Camiña JP; Gualillo O; Popovic V; Dieguez C; Casanueva FF
Endocrine; 2001 Feb; 14(1):95-9. PubMed ID: 11322508
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone-releasing peptides: clinical and basic aspects.
Argente J; García-Segura LM; Pozo J; Chowen JA
Horm Res; 1996; 46(4-5):155-9. PubMed ID: 8950613
[TBL] [Abstract][Full Text] [Related]
11. Effects of coadministered growth hormone (GH)-releasing hormone and GH-releasing hexapeptide on maladaptive aspects of obesity in Zucker rats.
Bercu BB; Yang SW; Masuda R; Hu CS; Walker RF
Endocrinology; 1992 Dec; 131(6):2800-4. PubMed ID: 1446617
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.
Pihoker C; Middleton R; Reynolds GA; Bowers CY; Badger TM
J Clin Endocrinol Metab; 1995 Oct; 80(10):2987-92. PubMed ID: 7559885
[TBL] [Abstract][Full Text] [Related]
13. Growth hormone secretagogues in critical illness.
Van den Berghe G
Horm Res; 1999; 51 Suppl 3():21-8. PubMed ID: 10592440
[TBL] [Abstract][Full Text] [Related]
14. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program.
Ehlers MR
Endocrine; 2001 Feb; 14(1):137-41. PubMed ID: 11322496
[TBL] [Abstract][Full Text] [Related]
17. On the actions of the growth hormone-releasing hexapeptide, GHRP.
Bowers CY; Sartor AO; Reynolds GA; Badger TM
Endocrinology; 1991 Apr; 128(4):2027-35. PubMed ID: 2004615
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
Giusti M; Marini G; Sessarego P; Peluffo F; Valenti S; Caratti C; Giordano G
Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
[TBL] [Abstract][Full Text] [Related]
19. Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy.
Vance ML; Kaiser DL; Martha PM; Furlanetto R; Rivier J; Vale W; Thorner MO
J Clin Endocrinol Metab; 1989 Jan; 68(1):22-8. PubMed ID: 2491864
[TBL] [Abstract][Full Text] [Related]
20. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II.
Ceda GP; Davis RG; Rosenfeld RG; Hoffman AR
Endocrinology; 1987 Apr; 120(4):1658-62. PubMed ID: 3104015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
